25 LLC’s Bio-Rad Laboratories Class A BIO Stock Holding History

25 LLC’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-24	Closed	-$9.55K	–	99
2023 Q2	$9.55K	Hold	24	–	–	0.01%	152
2023 Q1	$9.08K	Buy	+24	New	+$11.2K	0.01%	154

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

25 LLC's BIO Position: Q3 2023 in Review

25 LLC sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 24 shares — an estimated $9.55K sold.

25 LLC first reported a position in BIO in Q1 2023 and held it in 2 quarters. The position peaked at $9.55K in Q2 2023. 467 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

25 LLC reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
25 LLC sold 24 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $9.55K.
25 LLC first reported a position in Bio-Rad Laboratories Class A in Q1 2023 and held it in 2 quarters.
25 LLC's Bio-Rad Laboratories Class A position peaked at $9.55K in Q2 2023.
467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.